SG11201505944QA - PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS - Google Patents
PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSISInfo
- Publication number
- SG11201505944QA SG11201505944QA SG11201505944QA SG11201505944QA SG11201505944QA SG 11201505944Q A SG11201505944Q A SG 11201505944QA SG 11201505944Q A SG11201505944Q A SG 11201505944QA SG 11201505944Q A SG11201505944Q A SG 11201505944QA SG 11201505944Q A SG11201505944Q A SG 11201505944QA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- multiple sclerosis
- pparγ agonists
- pparγ
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361758641P | 2013-01-30 | 2013-01-30 | |
| PCT/US2014/012656 WO2014120538A1 (en) | 2013-01-30 | 2014-01-23 | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201505944QA true SG11201505944QA (en) | 2015-08-28 |
Family
ID=51223587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201505944QA SG11201505944QA (en) | 2013-01-30 | 2014-01-23 | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS |
| SG10201805896SA SG10201805896SA (en) | 2013-01-30 | 2014-01-23 | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201805896SA SG10201805896SA (en) | 2013-01-30 | 2014-01-23 | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9061020B2 (ko) |
| EP (1) | EP2950798B1 (ko) |
| JP (3) | JP5989921B2 (ko) |
| KR (2) | KR102056756B1 (ko) |
| CN (1) | CN105228622B (ko) |
| AU (1) | AU2014212740B2 (ko) |
| BR (1) | BR112015018048A2 (ko) |
| CA (1) | CA2899187C (ko) |
| EA (2) | EA201792096A3 (ko) |
| ES (1) | ES2883141T3 (ko) |
| HK (1) | HK1218510A1 (ko) |
| IL (2) | IL240051A (ko) |
| MX (1) | MX366765B (ko) |
| SG (2) | SG11201505944QA (ko) |
| WO (1) | WO2014120538A1 (ko) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| KR102056756B1 (ko) * | 2013-01-30 | 2019-12-17 | 인테크린 테라퓨틱스, 아이엔씨. | 다발성 경화증의 치료를 위한 PPARγ 작용제 |
| CN107683135A (zh) | 2015-03-09 | 2018-02-09 | 因特克林医疗有限公司 | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
| US20190167660A1 (en) * | 2016-08-18 | 2019-06-06 | Intekrin Therapeutics, Inc. | PPAR-gamma AGONIST FOR TREATMENT OF BONE DISORDERS |
| US20210379049A1 (en) * | 2016-08-18 | 2021-12-09 | Coherus Biosciences, Inc | PPAR-gamma AGONIST FOR TREATMENT OF BLOOD CANCERS |
| KR20190064583A (ko) * | 2016-09-13 | 2019-06-10 | 인테크린 테라퓨틱스, 아이엔씨. | Chs-131로 다발성 경화증의 치료 |
| SG11201909046XA (en) * | 2017-04-03 | 2019-10-30 | Coherus Biosciences Inc | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
| EA201992364A1 (ru) * | 2018-04-02 | 2020-03-23 | Кохерус Байосайенсис Инк. | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА |
| US20220387393A1 (en) * | 2019-11-06 | 2022-12-08 | Board Of Regents, The University Of Texas System | Methods for the treatment of dysmyelinating/demyelinating diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| US20050250820A1 (en) * | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
| EP2175845A2 (en) * | 2007-07-11 | 2010-04-21 | Cardoz AB | New combination for use in the treatment of inflammatory disorders |
| EP2242747A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| US20100087481A1 (en) * | 2008-10-03 | 2010-04-08 | Lee Kathleen M | Oral pharmaceutical formulations for antidiabetic compounds |
| WO2012040082A2 (en) * | 2010-09-21 | 2012-03-29 | Intekrin Therapeutics, Inc. | Antidiabetic solid pharmaceutical compositions |
| KR102056756B1 (ko) * | 2013-01-30 | 2019-12-17 | 인테크린 테라퓨틱스, 아이엔씨. | 다발성 경화증의 치료를 위한 PPARγ 작용제 |
-
2014
- 2014-01-23 KR KR1020167032282A patent/KR102056756B1/ko active IP Right Grant
- 2014-01-23 ES ES14746632T patent/ES2883141T3/es active Active
- 2014-01-23 US US14/162,723 patent/US9061020B2/en active Active
- 2014-01-23 AU AU2014212740A patent/AU2014212740B2/en active Active
- 2014-01-23 EP EP14746632.0A patent/EP2950798B1/en active Active
- 2014-01-23 WO PCT/US2014/012656 patent/WO2014120538A1/en active Application Filing
- 2014-01-23 SG SG11201505944QA patent/SG11201505944QA/en unknown
- 2014-01-23 JP JP2015556062A patent/JP5989921B2/ja not_active Expired - Fee Related
- 2014-01-23 CN CN201480006782.8A patent/CN105228622B/zh active Active
- 2014-01-23 MX MX2015009818A patent/MX366765B/es active IP Right Grant
- 2014-01-23 BR BR112015018048A patent/BR112015018048A2/pt not_active Application Discontinuation
- 2014-01-23 KR KR1020157023209A patent/KR20150133182A/ko active Application Filing
- 2014-01-23 EA EA201792096A patent/EA201792096A3/ru unknown
- 2014-01-23 EA EA201591399A patent/EA029216B1/ru unknown
- 2014-01-23 CA CA2899187A patent/CA2899187C/en active Active
- 2014-01-23 SG SG10201805896SA patent/SG10201805896SA/en unknown
-
2015
- 2015-05-08 US US14/707,122 patent/US9539249B2/en active Active
- 2015-07-21 IL IL240051A patent/IL240051A/en active IP Right Grant
-
2016
- 2016-06-07 HK HK16106520.8A patent/HK1218510A1/zh unknown
- 2016-08-09 JP JP2016156171A patent/JP6224189B2/ja active Active
- 2016-10-30 IL IL248594A patent/IL248594B/en unknown
-
2017
- 2017-01-10 US US15/402,941 patent/US9867816B2/en active Active
- 2017-10-03 JP JP2017193213A patent/JP6466540B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
| IL243536A0 (en) | Medical uses of cd38 agonists | |
| PL3080100T3 (pl) | Inhibitory lizyno-specyficznej demetylazy-1 | |
| IL252547A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| HK1222841A1 (zh) | 含碳原料的處理方法 | |
| IL240051A0 (en) | pparγ agonists for the treatment of multiple sclerosis | |
| EP3632467C0 (en) | INHIBITORS OF COMPLEMENT FACTOR H | |
| HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
| HK1218254A1 (zh) | 用拉喹莫德治療多發性硬化症 | |
| IL240763B (en) | The halopyrazoles as thrombin inhibitors | |
| HK1224305A1 (zh) | 用於治療重度低血糖症的新型化合物 | |
| EP2967824A4 (en) | VASO-OCCLUSIVE DEVICE COATED FOR THE TREATMENT OF ANEVRYSMS | |
| EP2986294A4 (en) | COMPOUNDS FOR THE TREATMENT OF PAIN | |
| HK1224303A1 (zh) | 用於治療嚴重低血糖的新穎的化合物 | |
| HK1224304A1 (zh) | 用於治療嚴重低血糖的新穎的化合物 | |
| GB201308466D0 (en) | Improved process for treatment of minewater | |
| EP2986295A4 (en) | COMPOUNDS FOR THE TREATMENT OF PAIN | |
| GB2525530B (en) | Treatment of hard surfaces | |
| GB201306411D0 (en) | Treatment of inflammatory conditions | |
| AU2013901359A0 (en) | Methods of Treatment |